Dent Neurologic

716-250-2000

Menu
Menu
Patient Portal
Pay My Bill
Referring Physicians
Request Medical Records
Provider Request

Research Study

Migraine prevention injection in patients with unsuccessful prior preventive treatments

Leave a Comment / Headache/Migraine, Research Study, Uncategorized / By

Migraine prevention injection in patients with unsuccessful prior preventive treatments The objective of the trial is to assess the efficacy of the study drug for prevention of migraine at different doses compared to placebo in patients who have failed multiple preventive treatments. Inclusion Criteria:  In order to be eligible, you have to have at least […]

Migraine prevention injection in patients with unsuccessful prior preventive treatments Read More »

Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2)

Leave a Comment / Headache/Migraine, Research Study, Uncategorized / By

Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) The purpose of the RELIEV-CM2 study is to evaluate ShiraTronics Migraine Therapy System’s ability to reduce the frequency of headaches for those living with chronic migraine. Inclusion Criteria: You may be eligible for this study if your doctor has diagnosed you with chronic migraine and you meet the

Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2) Read More »

Menstrual Migraine Prevention

Leave a Comment / Headache/Migraine, Research Study, Uncategorized / By

Menstrual Migraine Prevention using Ubrelvy This study will evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension Inclusion Criteria: In order to be eligible for this study, you must be at least 18 years old and have a diagnosis of Menstrual Migraine What to Expect

Menstrual Migraine Prevention Read More »

SANOFI EFC17504

Multiple Sclerosis, Research Study / By

SANOFI EFC17504 The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical

SANOFI EFC17504 Read More »

PIPELINE/CONTINUUM VISTA

Multiple Sclerosis, Research Study / By

PIPELINE/CONTINUUM VISTA This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis. Inclusion Criteria: 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years Without clinical MS relapse or treatment with corticosteroids within last 6

PIPELINE/CONTINUUM VISTA Read More »

INDIVIOR INDV-6000-406

Research Study / By

INDIVIOR INDV-6000-406 This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Inclusion Criteria: At least 18 years of age, has initiated treatment with SUBLOCADE within the last 3

INDIVIOR INDV-6000-406 Read More »

IGC Pharma

Alzheimer's, Research Study / By

IGC PHARMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease. Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What to

IGC Pharma Read More »

ACADIA RADIANT

Alzheimer's, Research Study / By

ACADIA RADIANT (Alzheimer’s Disease Psychosis) In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis. Inclusion Criteria:  50 years to 95  years of age Meets clinical criteria for possible or probable Alzheimer’s Disease Psychotic symptoms (hallucinations or delusions) for at least 2 months Availability of a designated study partner/caregiver What to Expect

ACADIA RADIANT Read More »

SUVEN CTP3S1502HT6

Alzheimer's, Research Study / By

SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria:  50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study

SUVEN CTP3S1502HT6 Read More »

ADCS BENFO-TEAM

Alzheimer's, Research Study / By

ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria:  50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study

ADCS BENFO-TEAM Read More »

Scroll to Top